Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: the recent experience at the Rizzoli Institute.
Bacci
G
G
Picci
P
P
Ferrari
S
S
Avella
M
M
Prever
B A
BA
Ruggieri
P
P
Casadei
R
R
Lari
S
S
Monti
C
C
Cazzola
A
A
D000206:Actuarial Analysis; D000293:Adolescent; D000671:Amputation, Surgical; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002648:Child; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005121:Extremities; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009336:Necrosis; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D016879:Salvage Therapy; D016019:Survival Analysis
D001761:Bleomycin; D003609:Dactinomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate